We tested 20 national brands of anti-diabetic
tablets, which consisted of 5 brands each of glibenclamide
(5 mg),
glipizide (5 mg), gliclazide (80 mg)
and metformin (500 mg).
Out of these, metformin is a biguanide and the rest are sulphonylureas.
We tested glibenclamide
and metformin
tablets as per IP and glipizide
and gliclazide as per BP.
All the tablets were tested for assay, identification,
uniformity of weight and disintegration as per IP and BP. Glibenclamide,
glipizide and gliclazide
were tested for the uniformity of content. The test was not prescribed
for the latter two but we conducted it in the interest of consumers.
Metformin
was tested for dissolution as per IP. All the tablets complied
with all the parameters given in the respective standards.
Since all the brands complied with the standards,
a major criterion for preferring one brand to another was their
price.
The price ranged from Rs. 4.65 to Rs. 63.70
for ten tablets. Gliclazide
tablets were the most expensive of all.